157 related articles for article (PubMed ID: 37470147)
1. PDE4 inhibitors for disease therapy: advances and future perspective.
Du B; Luo M; Ren C; Zhang J
Future Med Chem; 2023 Jul; 15(13):1185-1207. PubMed ID: 37470147
[TBL] [Abstract][Full Text] [Related]
2. Advances in the Development of Phosphodiesterase-4 Inhibitors.
Peng T; Qi B; He J; Ke H; Shi J
J Med Chem; 2020 Oct; 63(19):10594-10617. PubMed ID: 32255344
[TBL] [Abstract][Full Text] [Related]
3. Advances in the development of phosphodiesterase-4 inhibitors.
Li G; He D; Cai X; Guan W; Zhang Y; Wu JQ; Yao H
Eur J Med Chem; 2023 Mar; 250():115195. PubMed ID: 36809706
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders.
Wu C; Rajagopalan S
Obes Rev; 2016 May; 17(5):429-41. PubMed ID: 26997580
[TBL] [Abstract][Full Text] [Related]
5. The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors.
Paes D; Schepers M; Rombaut B; van den Hove D; Vanmierlo T; Prickaerts J
Pharmacol Rev; 2021 Jul; 73(3):1016-1049. PubMed ID: 34233947
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions.
Parikh N; Chakraborti AK
Curr Med Chem; 2016; 23(2):129-41. PubMed ID: 26572614
[TBL] [Abstract][Full Text] [Related]
7. PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes.
Jin J; Mazzacuva F; Crocetti L; Giovannoni MP; Cilibrizzi A
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511275
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
[TBL] [Abstract][Full Text] [Related]
9. The Past, Present, and Future of Phosphodiesterase-4 Modulation for Age-Induced Memory Loss.
Hansen RT; Zhang HT
Adv Neurobiol; 2017; 17():169-199. PubMed ID: 28956333
[TBL] [Abstract][Full Text] [Related]
10. Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement.
Wei X; Yu G; Shen H; Luo Y; Shang T; Shen R; Xi M; Sun H
Bioorg Chem; 2023 Jan; 130():106278. PubMed ID: 36413930
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential.
Roy D; Balasubramanian S; Krishnamurthy PT; Sola P; Rymbai E
Cell Mol Neurobiol; 2023 Aug; 43(6):2713-2741. PubMed ID: 37074485
[TBL] [Abstract][Full Text] [Related]
12. PDE4 as a target for cognition enhancement.
Richter W; Menniti FS; Zhang HT; Conti M
Expert Opin Ther Targets; 2013 Sep; 17(9):1011-27. PubMed ID: 23883342
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.
Li H; Fan C; Feng C; Wu Y; Lu H; He P; Yang X; Zhu F; Qi Q; Gao Y; Zuo J; Tang W
Br J Pharmacol; 2019 Jul; 176(13):2209-2226. PubMed ID: 30883697
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment.
Zhang R; Li H; Zhang X; Li J; Su H; Lu Q; Dong G; Dou H; Fan C; Gu Z; Mu Q; Tang W; Xu Y; Liu H
Eur J Med Chem; 2021 Feb; 211():113004. PubMed ID: 33218684
[TBL] [Abstract][Full Text] [Related]
15. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).
Cameron RT; Coleman RG; Day JP; Yalla KC; Houslay MD; Adams DR; Shoichet BK; Baillie GS
Biochem Pharmacol; 2013 May; 85(9):1297-305. PubMed ID: 23473803
[TBL] [Abstract][Full Text] [Related]
16. The PDE4 cAMP-Specific Phosphodiesterases: Targets for Drugs with Antidepressant and Memory-Enhancing Action.
Bolger GB
Adv Neurobiol; 2017; 17():63-102. PubMed ID: 28956330
[TBL] [Abstract][Full Text] [Related]
17. Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors.
Liu J; Zhang X; Chen G; Shao Q; Zou Y; Li Z; Su H; Li M; Xu Y
Eur J Med Chem; 2023 Dec; 262():115893. PubMed ID: 37918035
[TBL] [Abstract][Full Text] [Related]
18. Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei.
Ochiana SO; Bland ND; Settimo L; Campbell RK; Pollastri MP
Chem Biol Drug Des; 2015 May; 85(5):549-64. PubMed ID: 25283372
[TBL] [Abstract][Full Text] [Related]
19. DC591017, a phosphodiesterase-4 (PDE4) inhibitor with robust anti-inflammation through regulating PKA-CREB signaling.
Li H; Li J; Zhang X; Feng C; Fan C; Yang X; Zhang R; Zhu F; Zhou Y; Xu Y; Liu H; Tang W
Biochem Pharmacol; 2020 Jul; 177():113958. PubMed ID: 32251674
[TBL] [Abstract][Full Text] [Related]
20. Powerful relaxation of phosphodiesterase type 4 inhibitor rolipram in the pig and human bladder neck.
Ribeiro ASF; Fernandes VS; Martínez-Sáenz A; Martínez P; Barahona MV; Orensanz LM; Blaha I; Serrano-Margüello D; Bustamante S; Carballido J; García-Sacristán A; Prieto D; Hernández M
J Sex Med; 2014 Apr; 11(4):930-941. PubMed ID: 24754330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
